In addition to being a general anaesthetic, ketamine is a recognized drug of abuse. Many, if not all, drugs of abuse have been shown to increase dopamine efflux in the nucleus accumbens (NAc). As ketamine is optically active, we examined if its actions on dopamine efflux in the NAc were stereoselective. Slices of rat NAc were superfused with artificial CSF at 32°C. Dopamine efflux was evoked by electrical stimulation (1 or 20 pulses, 100 Hz) and measured using fast cyclic voltammetry. (Ϯ)-Ketamine 100 µmol litre -1 increased dopamine efflux (to mean 174 (SEM 17)% of control, PϽ0.05) and slowed dopamine uptake half-time (T 1 2 ) to 164 (17)% of control, as did (ϩ)-ketamine 100 µmol litre -1 (efflux 236 (16)% (PϽ0.001); uptake T 1 2 177 (25)% (PϽ0.05)). The (-)-isomer was inactive. The effect of (ϩ)-ketamine on dopamine efflux did not correlate with its action on dopamine uptake. (ϩ)-Ketamine increased dopamine efflux on single pulse stimulation but to a lesser extent than on 20 pulse trains (PϽ0.05). (ϩ)-Ketamine was unable to block the inhibitory effect of quinpirole on single pulse dopamine efflux. Neither MK 801 10 µmol litre -1 nor metoclopramide 1 µmol litre -1 had any effect on dopamine release after short train stimuli (20 pulses, 100 Hz). We conclude that the (ϩ)-isomer is the active form of ketamine and increases NAc dopamine efflux not by block of dopamine uptake, autoreceptors or NMDA receptors, but by mobilization of the dopamine storage pool to releasable sites. 1999; 82: 603-8 
allowed to recover from ketamine anaesthesia in quiet darkened rooms to reduce stimulation. 3 Ironically, the very properties that restrict its clinical use have made ketamine an increasingly popular drug of abuse, to the extent that it is often erroneously sold as 'Ecstasy'. 10 Its use is particularly prevalent at 'rave' parties and nightclubs. 11 Indeed, ketamine has been reported to induce stereotyped behaviour, 8 a common feature of many amphetamine-type psychomotor stimulants. 12 Many, if not all, drugs of abuse are thought to increase limbic dopamine release. [12] [13] [14] In the light of its abuse potential and capacity to induce stereotypies, it is possible that ketamine acts through dopaminergic mechanisms in the limbic system to induce hallucinations. Indeed, subanaesthetic doses of ketamine have also been shown to precipitate psychoses in schizophrenics. 15 The interactions of ketamine with the brain dopamine systems are complex and, in some cases, contradictory. For instance, ketamine seems not to modulate nigrostriatal dopamine function: nigral dopamine cell firing is unaffected 16 and dopamine turnover in the striatum is either unchanged 17 or decreased 10 by ketamine. Conversely, ketamine has been shown to increase the firing rate of ventral tegmental dopamine neurones 16 and induces hyper-locomotion in mice. 18 Both actions suggest that ketamine causes an increase in mesolimbic dopamine 'tone', consistent with its acknowledged abuse potential.
Ketamine is a mixture of two optical isomers. 19 Although the S(ϩ)-isomer is the more potent general anaesthetic, 20 the R(-)-isomer is, for instance, a more effective antagonist of acetylcholine-induced airway smooth muscle contraction, 21 suggesting that the pharmacological profile of the two isomers may differ. 22 Although ketamine causes hallucinations and is a drug of abuse, there is a possibility (as ketamine is essentially a mixture of two different drugs) that these properties may not be shared equally by the different isomers. The objective of our study was to examine the effects of ketamine on mesolimbic dopamine release and to determine the relative potency of the two isomers.
Materials and methods
All experiments were carried out on slices of the rat nucleus accumbens (NAc). Dopamine efflux was elicited by local electrical stimulation at tungsten microelectrodes and measured using fast cyclic voltammetry at carbon fibre microelectrode sensors implanted in the slice adjacent to the stimulating electrode.
Brain slices
Slices of NAc were prepared according to the basic method of Palij and colleagues. 23 In brief, male Wistar rats (150-200 g) were killed by cervical dislocation and their brains removed and placed in a bath of ice-cold artificial cerebrospinal fluid (aCSF). A block (approximately AP: ϩ11.0 to ϩ6.0 mm vs the interaural line 24 ) was cut and sequential slices of 350 µm were obtained using a vibrotome to acquire the desired rostrocaudal section. The NAc slices were transferred to a holding chamber of aCSF at room temperature for at least 1 h to recover from sectioning. Slices were then transferred to the recording chamber and superfused with aCSF at 32°C throughout the experiment. An equilibration time of 30 min before the first stimulation was used.
Electrical stimulation
Dopamine efflux was evoked by constant current pulses (0.1 ms, 10 mA) across a bipolar tungsten stimulating electrode (A-M Systems, Seattle; 300-400 µm tip separation). Stimulations consisting of either a single pulse or trains (20 pulses, 100 Hz) were applied at constant intervals (5 min for single pulses, 10 min for trains) throughout.
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Detection of dopamine efflux and uptake
Dopamine efflux and uptake were measured at carbon fibre (7 µm in diameter) microelectrodes. 25 The protruding carbon fibre was cut to a length of approximately 50-70 µm. The auxiliary electrode was a stainless-steel wire while the reference electrode was a standard silver-silver chloride disc (Clark Electromedical). The reference and auxiliary electrodes were placed conveniently in the chamber (submerged in aCSF), approximately 1 cm away from the tissue. The working electrode was positioned in the core of the NAc, close to the anterior commissure, while the stimulating electrode was placed approximately 200 µm away from the working electrodes in such an orientation that its tips were equi-distant from the working electrode tip.
Dopamine was detected using fast cyclic voltammetry. 26 Input to the potentiostat consisted of 1.5 cycles of a triangular waveform (-1.0 to ϩ1.4 V vs silver-silver chloride, scan rate of 480 V s -1 ) with an initial cathodic scan direction. This waveform was applied to the potentiostat twice per second, with the working electrode disconnected between scans. Current output and voltage input of the working electrode were displayed on a digital storage oscilloscope (Nicolet 310 DD). Digital subtraction of background current signals, before stimulation, from those obtained in response to a stimulus left the faradic current peak, resulting from oxidation of dopamine.
A peak sampling circuit was set to monitor current at the oxidation potential for dopamine (ϩ600 mV vs silversilver chloride). Peak sampled output was displayed on a chart recorder and captured on floppy disk via the digital storage oscilloscope, from which all measurements of peak dopamine efflux and uptake half-time (T 1 2 ) were obtained.
Drugs and chemicals
The following drugs and chemicals were obtained from the sources stated: ketamine hydrochloride (Sigma), S(ϩ)-and R(-)-ketamine (Parke-Davis), metoclopramide hydrochloride (SmithKline Beecham), MK801 (Tocris Cookson), quinpirole (Eli Lilly) and dopamine hydrochloride (Sigma). Stock solutions were prepared in distilled water (or HCl 0.1 mol litre -1 for dopamine) and kept frozen until the day of use.
Artificial CSF was composed of (mmol litre -1 ): NaCl 124, KCl 2.0, KH 2 PO 4 1.25, MgSO 4 . 7H 2 O 2.0, NaHCO 3 25, CaCl 2 2.0 and (ϩ)-glucose 11. The solution was gassed at 32°C with 95% oxygen-5% carbon dioxide before use.
Statistical analysis
All group results are expressed as mean (SEM). Groups were compared by one-way analysis of variance (ANOVA) using the Student-Newman-Keuls post hoc test (Graphpad Instat v3.00). Where only two groups were compared, Student's t test was used.
Results
Electrical stimulation in brain slices of the NAc caused dopamine release that was readily detectable by voltam- metry. This dopamine efflux was followed by removal of dopamine from the extracellular space by uptake. In controls, peak dopamine efflux was mean 279 (SEM 56) nmol litre -1 and uptake T 1 2 was 1.85 (0.22) s (nϭ14) after a stimulation train (20 pulses, 0.1 ms, 100 Hz). Figure 1A shows a typical peak sample trace of dopamine efflux and uptake in a control NAc slice and after exposure to (Ϯ)-ketamine 100 µmol litre -1 . Racemic ketamine increased dopamine release and slowed the rate of dopamine uptake. The effect of (Ϯ)-ketamine on dopamine efflux was concentration-dependent (Fig. 1B) . While (Ϯ)-ketamine 1 and 10 µmol litre -1 did not exert significant actions, 100 µmol litre -1 doubled dopamine efflux (PϽ0.05). At a still higher concentration (1 mmol litre -1 ), (Ϯ)-ketamine significantly reduced stimulated dopamine efflux (PϽ0.001). This effect was reversible by reperfusion with aCSF (data not shown). A concentration of 100 µmol litre -1 was used for all subsequent experiments on ketamine and its isomers.
The effect of ketamine on dopamine efflux and uptake was stereoselective (Fig. 2) . Both (ϩ)-ketamine (PϽ0.001) and the racemate (PϽ0.05) increased dopamine efflux after a stimulation train (20 pulses, 0.1 ms, 100 Hz). (-)-Ketamine had no effect. Furthermore, the effect of (-)-ketamine on dopamine efflux was significantly greater (PϽ0.01) than that of the racemate. Both (ϩ)-ketamine and the racemate increased dopamine uptake T 1 2 (both PϽ0.05). (-)-Ketamine had no effect.
The effects of ketamine on dopamine efflux were not the result of block of NMDA receptors or dopamine D 2 -type autoreceptors. The NMDA antagonist MK 801 (10 µmol litre -1 ) and the dopamine D 2 -type antagonist metoclopramide (1 µmol litre -1 ) had no effect on dopamine efflux or uptake on stimulation (20 pulses, 100 Hz, 0.1 ms). Table 1 shows the group data.
(ϩ)-Ketamine had no effect on dopamine D 2 -type autoreceptors in the NAc. The dopamine D 2 -type agonist quinpirole 1 µmol litre -1 almost abolished dopamine efflux (PϽ0.001) after single pulse stimulation (Fig. 3) . This effect was largely reversed (PϽ0.001) by the D 2 -type antagonist metoclopramide 1 µmol litre -1 but not by (ϩ)-ketamine 100 µmol litre -1 .
(ϩ)-Ketamine also increased dopamine efflux (PϽ0.05) and blocked dopamine uptake (PϽ0.01) on single pulse stimulation (Fig. 4) . The effect on dopamine efflux was significantly smaller on single pulse than on train stimulations (PϽ0.05). were compared after train stimulations (20 pulses, 100 Hz, 0.1 ms). There was no correlation between the ability of (ϩ)-ketamine to increase dopamine efflux and block dopamine uptake.
Discussion
Despite many valuable properties, the use of ketamine has been limited by the extent and variety of its side effects. Perhaps the most disturbing are the 'emergence phenomena' which include visual and auditory hallucinations. Most commonly, the patient is allowed to recover in a quiet and often darkened room with minimal sensory stimulation.
Parallels have repeatedly been drawn between the hallucinogenic properties of ketamine and other drugs of abuse, such as the amphetamines. As amphetamines increase limbic dopamine release, one might speculate that ketamine psychoses may also involve the limbic dopamine systems.
From our study, it is clear that ketamine has concentrationdependent actions on dopamine efflux and uptake in the NAc. At 100 µmol litre -1 , ketamine increased dopamine efflux while it was decreased at 1 mmol litre -1 . It has been shown that ketamine blocks sodium channels at high (mmol litre -1 ) concentrations 27 and this effect may explain attenuation of dopamine efflux seen here. Indeed, ketamine has been shown to inhibit most voltage-operated ion channels at these concentrations. 28 However, the reduction in dopamine release by the higher concentration is unlikely to be clinically meaningful as previous studies by Livingston and Waterman 29 have shown that rat brain concentrations of ketamine during anaesthesia are approximately 100 µmol litre -1 and thus in all subsequent experiments we used this concentration. Nevertheless, it is worth remembering that ketamine concentrations in the rat brain can peak as high as 400 µmol litre -1 immediately after induction 30 while plasma concentrations are several-fold lower. Thus a concentration of 100 µmol litre -1 in the aCSF may translate to a higher tissue concentration.
The effect of ketamine on dopamine efflux and uptake is strikingly stereoselective. Data in Figure 2 show clearly that (ϩ)-ketamine is the active form with (-)-ketamine having no effect at 100 µmol litre -1 . Several studies have shown that ketamine can, under certain conditions, increase limbic dopamine release in vivo. For example, Lindefors, Barati and O'Connor 31 showed that ketamine increased dopamine release in the prefrontal cortex five-fold, while others have shown increased formation of DOPAC and HVA in the nucleus accumbens, 16 suggesting enhanced turnover. Furthermore, ketamine also blocks dopamine uptake in brain slices (Fig. 2B ) consistent with previous reports on synaptosomes [32] [33] [34] The effects are stereoselective, and are exhibited only by (ϩ)-ketamine and the racemate.
One might conclude that the effects of ketamine on dopamine efflux could be explained by action on dopamine uptake. We have shown previously that several recognized dopamine uptake blockers increase both dopamine uptake T 1 2 and dopamine efflux. 8 35 36 For those uptake blockers devoid of direct releasing actions, the effects on one measure correlate well with those on the other. However, this was not the case with ketamine. Figure 5 shows that there was no direct relationship between the ability of (ϩ)-ketamine to increase dopamine efflux and block dopamine uptake and that, in general, greater effects were observed on dopamine efflux than uptake. It would appear that the ability to increase dopamine efflux is a parallel property independent of dopamine uptake block.
Ketamine is known to block NMDA receptors 37 38 with the (ϩ)-isomer being the more potent enantiomer. We have shown previously that NMDA receptor block (by CGS 19755) increases striatal dopamine efflux on 20 pulse stimulation trains 39 and thus the effect of ketamine on dopamine release could potentially be caused by NMDA receptor block. However, the potent NMDA antagonist MK 801 (10 µmol litre -1 ) had no effect on stimulated NAc dopamine efflux (Table 1) , although this concentration has been shown to modulate ischaemia-induced striatal dopamine release. 40 This strongly suggests that NMDA receptors do not modulate limbic dopamine efflux under these experimental conditions and thus that the observed action of ketamine on limbic dopamine efflux cannot be explained by its known action at NMDA receptors. This is supported further by data in the literature which shows that, although there is a strong dopaminergic-glutamatergic link in the action of the amphetamine-type stimulants, NMDA antagonists typically attenuate the expression of psychomotor behaviours. 41 As it is known that dopamine release in the NAc is under autoreceptor control, another possibility is that ketamine could increase dopamine efflux by autoreceptor block. Such a mechanism has been speculated by others. 42 However, for several reasons, this was not the case. First, metoclopramide 607 1 µmol litre -1 did not increase dopamine release on 20 pulse stimulation trains (see Table 1 ), although it blocked the effect of the autoreceptor agonist quinpirole (Fig. 3) . Metoclopramide can block endogenous autoreceptor activation when the stimulus parameters are appropriate. 43 Second, (ϩ)-ketamine did not block the effect of quinpirole on dopamine efflux (Fig. 3) . Finally, when single pulse stimulations were used, (ϩ)-ketamine increased dopamine efflux (Fig. 4) although under these conditions there is no endogenous autoreceptor tone to antagonize.
The effect of (ϩ)-ketamine on efflux was not caused directly by uptake block. Normally, pure uptake blockers, such as GBR 12909, increase dopamine efflux equally after single pulse and 20 pulse stimulations. 36 Conversely, those drugs that mobilize the dopamine storage pool (such as nomifensine and amfonelic acid) increase dopamine efflux to an approximately two-fold greater extent on trains than on single pulse stimuli. 36 (ϩ)-Ketamine had an approximate two-fold larger effect (PϽ0.05) on dopamine release when trains were used ( Fig. 2A) as opposed to single pulse stimuli (Fig. 4) . Thus it is likely that ketamine has the capacity to mobilize the dopamine storage pool. This action is independent of uptake block and has been shown to apply to several of the nonamphetamine class psychomotor stimulants, such as amfonelic acid and methylphenidate. 44 It is thought that these drugs act to transfer or 'mobilize' the normally inert neuronal storage pool of dopamine to the 'newly synthesized' pool where it is then available for neurogenic, impulse-dependent release. 45 In summary, we have shown that ketamine increased dopamine release in the NAc at clinical concentrations. The effect was stereospecific, being largely (if not wholly) a result of the (ϩ)-isomer. (ϩ)-Ketamine also blocked dopamine uptake. The ability of (ϩ)-ketamine to increase dopamine efflux was not the result of uptake block or NMDA receptor antagonism. Furthermore, (ϩ)-ketamine did not block dopamine autoreceptors. The effects of (ϩ)-ketamine on dopamine efflux were consistent with mobilization of the dopamine storage pool to releasable sites, thus increasing impulse-dependent efflux. In human studies, (ϩ)-ketamine is 2-4 times more potent as an anaesthetic. 46 If the ability to increase limbic dopamine release causes hallucinations, it may not be possible to separate this from its anaesthetic effects.
